April 29th 2025
At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and navigate a shifting health care environment.
Rates for reimbursement cuts will be lower than expected within Medicare Advantage plans; financial safety nets, in the form of Social Security and Medicare, are likely to be unable pay full benefits; CDC teams experience symptoms similar to East Palestine, Ohio, residents following train derailment
Read More
FDA Outlines Next Steps to Weave Digital Health Data Into Clinical Trials
March 24th 2023Digital health data can facilitate the participation of underrepresented and diverse patient populations in clinical trials, but first the FDA must build its capability to evaluate such information in its regulatory processes for new drug development.
Read More
Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says
March 21st 2023A panel assembled at the American Academy of Dermatology 2023 Annual Meeting encouraged the audience of dermatologists to advocate together for needed changes in payment, access, and practice.
Read More
Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care
March 18th 2023Speakers at the American Academy of Dermatology 2023 Annual Meeting highlighted the potential of DataDerm to tell the story of dermatological care in the United States, but some also cautioned that the registry only reflects those who have access to care in the first place.
Read More
Biden Administration Releases Drug Rebate List, Promotes End of Vaccine Cost Sharing
March 15th 2023The Biden administration released the list of 27 Medicare Part B drugs that are subject to rebates back to the government for having price increases that rose faster than inflation as well as the removal of out-of-pocket costs for some vaccines covered under Part D.
Read More
Community social determinants of health such as rurality and low socioeconomic status moderate the association between an individual’s race and emergency care use.
Read More
Development of a Medicare Plan Dashboard to Promote Health Equity
Health plans use data to decide on quality improvement initiatives. Having a dashboard that characterizes how equitably plans are serving their enrollees would promote health equity.
Read More
What We’re Reading: Rare Disease Drug Approved; Congress and PBMs; FDA Panel Splits on RSV Shot
March 1st 2023The FDA approved the first drug for the rare disease Friedreich’s ataxia; House Republicans seek information from pharmacy benefit managers (PBMs); FDA panel narrowly supports respiratory syncytial virus (RSV) vaccine for older adults.
Read More
Association Between Use of Clinician Performance Information and Patient Experience
High patient experience scores were associated with the collection and use of any clinician performance information, especially with whether the practice shared this information internally to compare.
Read More
Social Security and Medicare spending could double by 2023; FDA panel experts want naloxone to be available over the counter after the drug information is revised; Moderna announced its COVID-19 vaccines will stay free, and the Biden administration might keep tests and treatments free for the uninsured.
Read More
CMS Practice Assessment Tool Validity for Alternative Payment Models
Using data from 632 primary care practices, the authors show that the CMS Practice Assessment Tool has adequate predictive validity for participation in alternative payment models.
Read More
Addressing Maternal Mortality in Medicaid by Focusing on Mental Health
February 15th 2023On this episode of Managed Care Cast, we speak with Inland Empire Health Plan, a managed care plan serving more than 1.4 million residents on Medi-Cal in California, about a new maternal mental health program aimed at supporting new mothers, both before they give birth and afterward.
Listen
HHS wants to require nursing homes to disclose more ownership and management information; privacy advocates warn that mental health data can legally be sold from certain platforms not covered by the Health Insurance Portability and Accountability Act; the FDA won’t review Soligenix’s cancer drug proposal because of an insufficient application.
Read More